Şunu aradınız:: immunodefiċjenti (Maltaca - İngilizce)

ma jeżistix tagħrif dwar l- użu ta ’ menitorix f’ persuni immunodefiċjenti.
no data are available on the use of menitorix in immunodeficient subjects.

l-immunoġeniċità tal-vaċċin tista’ titbaxxa permezz ta’ trattament immunosoppressiv jew immunodefiċjenti.
the immunogenicity of the vaccine may be reduced by immunosuppressive treatment or immunodeficiency.

nies li huma immunodefiċjenti jew qed jieħdu mediċini biex titrażżan l- immunità għandhom jevitaw li jmissu dan il- vaċċin.
this vaccine should not be handled by persons who are immunodeficient or taking immunosuppressive drugs.

it-tipi u r-rati ta’ kanċers speċifiċi kienu dawk mistennija f’popolazzjoni immunodefiċjenti bil-bosta.
the types and rates of specific cancers were those expected in a highly immunodeficient population.

rotarix għandu jingħata b’prekawzjoni lil individwi b’kuntatti mill-qrib immunodefiċjenti, bħal individwi b’tumuri malinni, jew b’xi mod ieħor immunokompromessi jew individwi li jkunu fuq terapija immunosoppressiva.
rotarix should be administered with caution to individuals with immunodeficient close contacts, such as individuals with malignancies, or who are otherwise immunocompromised or individuals receiving immunosuppressive therapy.